Abstract
Quantitative structure-activity relationships (QSAR) of 65 different molecular series histone deacetylase inhibitors (HDACIs) with only one common pyrrole ring were studied by using comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) and hologram quantitative structure-activity relationship (HQSAR). The leave-one-out cross-validation q2 values of CoMFA, CoMSIA and HQSAR models were 0.623, 0.662 and 0.716, and non-cross-validated r2 values were 0.952, 0.909 and 0.891, respectively. The contour maps and atom contribution map provided helpful visualization information for structural modification of the HDACIs for better activity. A further docking study was carried out by using Surflex-dock method. Sixty-five compounds were docked into histone deacetylase (PDB ID 1T64). A reasonable docking model between inhibitors and the protein was obtained. The interaction between ligands and the receptor can reveal the binding mode of the HDAC inhibitors and HDAC enzyme. According to QSAR and docking results, eight new molecules were proposed, and their activities were predicted by using the established QSAR model and docking method. The results indicated that the proposed potential molecules have a potent activity.
Keywords: CoMFA, CoMSIA, HQSAR, HDACIs, Surflex-dock
Letters in Drug Design & Discovery
Title:QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs)
Volume: 9 Issue: 4
Author(s): Yuhong Xiang, Liang Zhang, Zhuoyong Zhang
Affiliation:
Keywords: CoMFA, CoMSIA, HQSAR, HDACIs, Surflex-dock
Abstract: Quantitative structure-activity relationships (QSAR) of 65 different molecular series histone deacetylase inhibitors (HDACIs) with only one common pyrrole ring were studied by using comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) and hologram quantitative structure-activity relationship (HQSAR). The leave-one-out cross-validation q2 values of CoMFA, CoMSIA and HQSAR models were 0.623, 0.662 and 0.716, and non-cross-validated r2 values were 0.952, 0.909 and 0.891, respectively. The contour maps and atom contribution map provided helpful visualization information for structural modification of the HDACIs for better activity. A further docking study was carried out by using Surflex-dock method. Sixty-five compounds were docked into histone deacetylase (PDB ID 1T64). A reasonable docking model between inhibitors and the protein was obtained. The interaction between ligands and the receptor can reveal the binding mode of the HDAC inhibitors and HDAC enzyme. According to QSAR and docking results, eight new molecules were proposed, and their activities were predicted by using the established QSAR model and docking method. The results indicated that the proposed potential molecules have a potent activity.
Export Options
About this article
Cite this article as:
Yuhong Xiang, Liang Zhang, Zhuoyong Zhang , QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs), Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799860033
DOI https://dx.doi.org/10.2174/157018012799860033 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Role of DEAD-Box RNA Helicase rck/p54 in Cancer Cells
Current Drug Therapy Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation
Recent Patents on Anti-Infective Drug Discovery Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research The Concept of a Green Drug, Curcumin and It ’ s Derivatives as a Model System
Mini-Reviews in Organic Chemistry Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Targeting Microtubules for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review
Current Drug Metabolism Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Current Cancer Drug Targets Soft Bipolar Spectrum and Staging in Bipolar Disorder
Current Psychiatry Reviews Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers
Current Medicinal Chemistry - Anti-Cancer Agents Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs Comprehensive Quality Management (CQM) in the PLCO Trial
Reviews on Recent Clinical Trials Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism Recent Insights on the Medicinal Chemistry of Metal-Based Compounds: Hints for the Successful Drug Design
Current Medicinal Chemistry Idiotype Vaccines for Human B-Cell Malignancies
Current Pharmaceutical Design